Segment Reporting

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

The Company’s structure is aligned with how the chief operating decision maker (“CODM”) reviews the business, makes investing and resource allocation decisions and assesses operating performance. The Company’s CODM is its Chief Executive Officer. At December 31, 2024, the Company has identified one reportable segment: GeneDx inclusive of Legacy GeneDx and Legacy Sema4 data revenues and associated costs. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Other represents the revenues and costs associated with the Legacy Sema4 diagnostics business which was completely shut down in 2023.

The CODM evaluates segment performance based on revenue and adjusted gross profit.

	Year ended December 31,
	2024						2023
	GeneDx		Other		Total		GeneDx		Other		Total
Revenue	$	302,293	$	3,157	$	305,450	$	194,376	$	8,190	$	202,566
Adjusted cost of services	106,376		145		106,521		106,983		2,305		109,288
Adjusted gross profit (1)	195,917		3,012		198,929		87,393		5,885		93,278
Reconciliations:
Depreciation and amortization					4,047						4,350
Stock-based compensation					431						(1,217)
Restructuring charges					54						139
Gross profit					$	194,397					$	90,006

(1)Adjusted cost of services and adjusted gross profit exclude depreciation and amortization expense, stock-based compensation expense and restructuring costs.

Management manages assets on a total company basis, not by reporting segment. The CODM does not regularly review any asset information by reporting segment and, accordingly, the Company does not report asset information by reporting segment.